Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.60 |
| ▸ | MAG | P20916 | 7/20 | 0.51 |
| ▸ | SELP | P16109 | 4/20 | 0.49 |
| ▸ | SELL | P14151 | 2/20 | 0.49 |
| ▸ | SELE | P16581 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29361920 | 1.00 | SIGLEC7 (0.60) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL29361042 | 0.98 | SIGLEC7 (0.59) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL23087055 | 0.97 | SIGLEC7 (0.64) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL29361332 | 0.97 | SIGLEC7 (0.64) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL21552197 | 0.97 | SIGLEC7 (0.64) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL29693389 | 0.97 | SIGLEC7 (0.64) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL29693395 | 0.95 | SIGLEC7 (0.59) | SIGLEC7MAGSELPSELL | |
| SCHEMBL20455686 | 0.95 | SIGLEC7 (0.59) | SIGLEC7MAGSELPSELL | |
| SCHEMBL20455685 | 0.95 | SIGLEC7 (0.59) | SIGLEC7MAGSELPSELL | |
| SCHEMBL30739463 | 0.95 | SIGLEC7 (0.59) | SIGLEC7MAGSELPSELL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230132366-A9 | METHODS FOR TREATING DYSREGULATED LIPID METABOLISM | DENALI THERAPEUTICS INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230092681-A1 | METHODS FOR THE TREATMENT OF HUNTER SYNDROME | DENALI THERAPEUTICS INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-11357249-B2 | Synthetic milk compositions comprising n-6 eicosatrienoic acid and polar lipids for infants younger and older than three months for healthy establishment of cognitive function | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2022-06-14 | — | — | US | disclosed |
| US-11357252-B2 | Synthetic milk compositions for optimal growth and development and prevention of obesity in male and female infant and children | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2022-06-14 | — | — | US | disclosed |
| US-20220025065-A1 | LYSOSOMAL STORAGE DISORDER BIOMARKERS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS INC. (US) | 2022-01-27 | — | — | US | disclosed |